Raymond James downgrades Sionna Therapeutics stock rating on trial failure
Raymond James has downgraded Sionna Therapeutics to Market Perform from Outperform after the company's Phase 2a trial for SION-719 in combination with Trikafta failed to meet its primary endpoint, showing only a 1.0 mmol/L sweat chloride reduction against a target of 10 mmol/L. This …